Printer Friendly

Daxor Corporation Announces Appointment of Dr. Donald Margouleff to Director of Nuclear Medicine.

NEW YORK -- Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, announces that Dr. Donald Margouleff, an expert in the field of Nuclear Medicine, has joined its staff as Daxor's Director of Nuclear Medicine. Nuclear Medicine consulting services will be offered to the medical industry under his direction.

Dr. Margouleff is Board certified in both Nuclear Medicine and Internal Medicine. He holds the title of Professor of Clinical Medicine at the New York University School of Medicine and is Chief Emeritus of the Division of Nuclear Medicine of the North Shore University Hospital in Manhasset, N.Y.

In 1987, before PET was generally accepted in the field of medicine, a prototype PET scanner and medical Cyclotron were installed under his direction at North Shore University Hospital. In addition to the clinical and research applications, in collaboration with Cardinal Health, Dr. Margouleff set up a system which now delivers PET tracer to many hospitals in the New York metropolitan area.

Dr. Margouleff was appointed chairman of the Radiological Health Advisory Committee to the Bureau of Environmental Radiation Protection of the New York State Health Department in 1982 and served in this capacity until 2005. He is a Fellow of the American College of Physicians and is a member of the American Thyroid Association. He is on the editorial board of the journal Clinical Nuclear Medicine.

Dr. Margouleff's services would be available to hospitals that are considering expanding nuclear medicine services and incorporating tests such as blood volume analysis. Blood volume measurement is essential for accurate diagnosis and treatment in conditions such as congestive heart failure, anemia, and syncope (fainting). These are conditions in which blood volume derangements are common. He will also be available to organizations that manufacture and distribute nuclear medicine instrumentation or are involved in the production of new radio- pharmaceuticals and invites inquiries regarding his consulting services.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. Idant Laboratories, Daxor's subsidiary, started the first personal frozen blood storage programs and one of the first frozen semen storage centers. For more information visit Daxor's website www.Daxor.com.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 5, 2006
Words:352
Previous Article:Renesas Technology's DrMOS-Compliant Power Switching Device Achieves Industry's Highest Efficiency, Reducing Heat for CPU Power Supplies.
Next Article:Anti-Defamation League to Honor Ambassador Rockwell A. Schnabel, Chairman of The Sage Group, with Humanitarian Award.
Topics:


Related Articles
Brass tracks.
NUCLEAR PHYSICIST WILL HEAD FBI'S TROUBLED CRIME LAB.
Daxor Announces Integrated Diagnostic Imaging of Staten Island Acquires Blood Volume Analyzer BVA-100.
Daxor Announces Medical University of South Carolina Acquires Blood Volume Analyzer BVA-100.
Daxor Announces St. Francis Medical Center of Honolulu, HI Acquires Blood Volume Analyzer BVA-100.
Daxor Announces Palmetto Health Baptist Columbia of Columbia, SC Purchases Blood Volume Analyzer BVA-100.
Daxor Announces Westchester Medical Center of Valhalla, NY Acquires Blood Volume Analyzer BVA-100.
Daxor Announces Christiana Care Health System of Newark, DE Purchases Blood Volume Analyzer BVA-100.
Daxor Announces Lenox Hill Hospital of New York, NY Acquires Blood Volume Analyzer BVA-100.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters